Koninklijke Philips NV (PHIA) fair value: what the stock is really worth
As of Nov 6, 2026: fair value (intrinsic value) of Koninklijke Philips NV stock €15.23, price €27.33, that is 44.3% below the price, quality 64 out of 100. Rating: strongly overvalued. Calculated from audited financials with 22 of our 26 valuation models and 37 quality factors, updated daily.
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year. As of Nov 6, 2026.
How to read this chart
60‑month range €9.54 – €31.68 · fair‑value band €9.63 – €23.60 · the €27.33 price screens above the €15.23 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). 2 fiscal years are left out: there the valuation rested on only a fraction of the usual models. As of Nov 6, 2026.
Follow Koninklijke Philips in your weekly email
Every Wednesday you see whether Koninklijke Philips is on track or worth a review, plus price against fair value. Free, up to 3 stocks.
We send you a confirmation link. Unsubscribe with one click.
Koninklijke Philips N.V. operates as a health technology company in North America, the Greater China, and internationally. It operates through Diagnosis & Treatment, Connected Care, and Personal Health segments.
Show moreShow less
The company provides diagnostic imaging solutions, includes ultrasound business unit, magnetic resonance imaging, computed tomography, and diagnostic x-ray; Image Guided Therapy, including image guided therapy systems and image guided therapy devices.
It also offers monitoring, enterprise informatics, and sleep and respiratory care, as well as personal health. Koninklijke Philips N.V. has strategic alliance with WellSpan Health to advanced imaging and diagnostics technology products and platforms.
The company was formerly known as Koninklijke Philips Electronics N.V. and changed its name to Koninklijke Philips N.V. in May 2013. Koninklijke Philips N.V. was founded in 1891 and is headquartered in Amsterdam, the Netherlands.
Stock analysis
Koninklijke Philips NV (PHIA) currently trades at €27.33, while our model-based Fair Value estimate is €15.23, 44% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Multiples group reads highest at a median of €20.16 per share, and 2 of the 22 models we run sit above the €27.33 price.
Bear case: the Dividend Discount group reads lowest at €3.80, and 20 of the 22 models stay below the price. Data coverage for this calculation is medium.
Scenario range: €9.63 (bear) to €23.60 (bull), the price of €27.33 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 64/100 (solid quality), in the Healthcare sector.
Mixed Growth: Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
Koninklijke Philips NV reported revenue of €17.8B in FY2025 versus €17.2B in FY2021, a compound +1.0%/yr. Reported net income was €896M in FY2025, compounding −27.9%/yr from FY2021.
Key figures
Market cap €26.5B Large · P/E ratio 66.7 · P/S ratio 3.35 · EPS (TTM) €0.4100 · Dividend yield 3.1% · Net margin 5.0% · Return on equity 8.6% · Return on assets (EBIT) 0.9% (5-year average).
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 38 out of 100 (low confidence).
What moves the price
The last reported earnings sit well below what analysts expect (earnings in transition, for example after write-downs or an earnings dip); whether the stock is cheap or expensive hinges on the expected recovery actually arriving. Read the fair value with that caveat.
The share trades about 1% below its 52-week high and 29% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −44%, PHIA screens richer than that median.
Fair Value models
Bear€9.63Fair Value €15.23Bull€23.60
Price €27.33 · Downside -44.3%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above starts from their evidence-weighted blend, not from a single model. In cyclical trough or peak years, after dilution or a stock split it is adjusted afterwards, so it can sit above or below the models.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.Coverage ⓘCoverage = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.55/100
Spin-off in 2024: revenue and profit before it include the divested business. Growth is measured afresh from 2024.
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate. Basis: adjusted.
−0.3%
Earnings growth per share plus dividend.
Earnings per share, growth per year−3.4%
Dividend (yield on the price)3.1%
Per share before 2024divided by the spin-off factor 1.0342
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.−4.9% vs 3.9%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.8% → 9%
Pace: the 5-year rate starts in 2020 (pandemic)
⚠ Revenue per share shrinking 2.1%/yr over ~10Y (margins eroding too) ⓘStructural-decline marker: revenue PER SHARE has fallen over the last decade (robust median trend, not a single year). Backtested across 2005 to 2017, such businesses trailed the market by about 2.5 percentage points per year. Display only: it does not change the fair value or the quality score.
Growth Forecast
A lot of optimism in the price
The price assumes more growth than the company has delivered so far and more than analysts expect.
What the price assumes ⓘThis turns our valuation around: instead of asking what the share is worth, it asks what growth the current price requires. It uses the cash the company keeps after all spending (free cash flow), the same discount rate as our models, five years of growth, then slowing evenly to 2 % a year by year ten. Compared with the analysts' sales forecasts extended to the same five years (at least three analysts, for context only, it does not enter the Fair Value): within 3 percentage points counts as "in line" (amber), below that little optimism (green), above that a lot of optimism (red).
+16.0%
Yearly growth needed for the next five years to justify today's price.
What forecasts expect ⓘAnalysts publish sales forecasts for the next two fiscal years. For the years after that, growth slows evenly to 2 % a year by year ten (2 % is the long-run rate our models use). Projected years are marked as such.
+3.6%
Yearly sales growth analysts expect, extended to five years.
After inflation (euro area: IMF forecast 2.2% a year to 2030, 2.6% from 2016 to 2025) that is about +13.5% a year for the price and +1.3% for the forecasts.
News mood ⓘNews mood, the average tone of recent news (98 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.Neutral
Recent news coverage is roughly neutral, about typical for how stocks are covered.
AI conclusion: Limited public data leaves no clear signals of durable advantages, while the main strength lies in the resolved Dutch inquiry that may free focus for imaging and oral care lines.
Main risk: Ongoing lawsuits, DOJ and SEC investigations plus the FDA consent decree restricting US sales of certain sleep and respiratory devices could continue to tie up management attention and resources in the respiratory care segment.
Bull case: Philips could resolve remaining regulatory matters and redirect focus fully to its imaging and oral care businesses, leveraging AI enhancements to strengthen its competitive position in diagnostics.
Bear case: Prolonged legal and regulatory scrutiny could divert significant resources from core imaging operations and limit product launches or market access in respiratory care for years.
Philips secured a Dutch court ruling that dismissed shareholder calls for an inquiry into its 2021 sleep apnea device recall. The decision found the company’s controls aligned with standards and that key risk data surfaced only months before the action. Does this legal clarity now let the medical devices business concentrate on its imaging and oral care lines, or do probes in other countries continue to tie up resources and attention?
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Medical Devices · 318 stocks
Beats the industry median on 6/14 measures
A mixed picture versus its industry peers.
Valuation
Quality Score64 · Above median
Fair Value upside−44.3% · Below median
Profitability
Return on equity (12 months)8.6% · Above median
Return on assets3.3% · Above median
Net margin (12 months)5.4% · Below median
Operating margin (12 months)3.8% · Below median
Growth and dividend
Revenue growth (quarter YoY)2.1% · Below median
Dividend yield (12 months)3.1% · Above median
Balance sheet
Debt / equity0.55× · Highest 25%
Valuation Multiplesvs Medical Devices median · lower = cheaper
P/E (12 months)66.7× · Priciest 25%
P/B2.69× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months)1.66× · Cheaper than median
Price / free cash flow (fiscal year)32.7× · Pricier than median
EV/EBITDA14.9× · Pricier than median
PEG0.95× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 6
FUTURE (revenue growth)11· sector 36
PAST (return on equity)34· sector 17
HEALTH (low debt)72· sector 98
DIVIDEND (yield)62· sector 34
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Is Koninklijke Philips NV (PHIA) overvalued or undervalued?
As of Nov 6, 2026, our model estimates a fair value of €15.23 versus a price of €27.33, about 44% lower (overvalued).
What is the fair value of PHIA?
Our model-based fair value for Koninklijke Philips NV is €15.23 (as of Nov 6, 2026), built from audited fundamentals. The current price: €27.33.
What is the quality score of PHIA?
Koninklijke Philips NV has a Quality Score of 64/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Koninklijke Philips NV (PHIA)?
Our model-based price target is the fair value of €15.23 (as of Nov 6, 2026) from 22 valuation models. Cautious scenario €9.63, optimistic scenario €23.60. It is a calculation from audited fundamentals, not an analyst target.
What is the Koninklijke Philips NV stock forecast for 2026?
Our models put fair value at €15.23, about 44% lower versus a price of €27.33 (overvalued). Cautious scenario €9.63, optimistic scenario €23.60. The calculation is refreshed regularly with new filings.
What is the revenue of Koninklijke Philips NV (PHIA)?
Koninklijke Philips NV reported trailing-twelve-month revenue of about €17.8B (latest available figure, as of Nov 6, 2026).
Does Koninklijke Philips NV pay a dividend?
Koninklijke Philips NV currently shows a dividend yield of 3.11% relative to its recent price (as of Nov 6, 2026).
How much is the dividend of Koninklijke Philips NV (PHIA) and when is the ex-dividend date?
Koninklijke Philips NV pays a dividend of €0.85 per share a year, a dividend yield of 3.1%. The last ex-dividend date was May 12, 2026. A dividend has been paid every year since 1994. The payout ratio is 174% of earnings (on adjusted earnings, reported 207%). Free cash flow covers the dividend 1.09 times. Our assessment: Payout strained. The dividend exceeds reported earnings (though reported profit is often depressed by one-off charges), and free cash flow only just covers it (or coverage is unknown). Not an emergency, but little room for error.
What growth is priced into Koninklijke Philips NV (PHIA)?
For today's price to be fair in a discounted-cash-flow model, Koninklijke Philips NV would have to grow free cash flow by +16.0 % per year for five years (discount rate 8.6 %, then slowing evenly to 2 % perpetual growth by year ten). Over the last 5 years revenue grew -1.8 % per year. As of Nov 6, 2026.
What discount rate (WACC) does the fair value of PHIA use?
Our models discount Koninklijke Philips NV at 8.6 %: a base by market capitalisation (large), damped by beta 0.81, country premium for Netherlands. The same rate applies in all 26 models.
What is a reverse DCF?
A reverse DCF turns the usual calculation around. Instead of deriving a value from assumptions, it takes today's price as given and asks: what free-cash-flow growth would a company have to deliver for exactly this price to be fair? The result is not a forecast but the expectation already priced in. For Koninklijke Philips NV that is +16.0 % per year for five years, then slowing evenly to 2 % by year ten, using the same discount rate (8.6 %) and the same formula as our fair value.
How much growth has Koninklijke Philips NV (PHIA) delivered so far?
Over the past 5 years revenue at Koninklijke Philips NV grew -1.8 % a year. The price currently implies free-cash-flow growth of +16.0 % per year. Comparing the two shows how much confidence is in the price: if it demands more than has been delivered, the business has to accelerate for the maths to work.
How fast is the sector of Koninklijke Philips NV (PHIA) growing?
The median revenue growth in the sector is +6.2 % a year. That is the yardstick for the growth priced into Koninklijke Philips NV (+16.0 % per year): it shows whether the expectation is within the usual range or beyond it.
What is the free cash flow yield of Koninklijke Philips NV (PHIA)?
The free-cash-flow yield on the price is 3.41 %: that much free cash flow Koninklijke Philips NV produces per unit of market value. When it exceeds the discount rate of our models (8.6 %), the business already earns more than its cost of capital demands, and the price needs little additional growth.
What is the intrinsic value of Koninklijke Philips NV (PHIA)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Koninklijke Philips NV it is €15.23 per share (as of Nov 6, 2026), against a price of €27.33. It is the blended result of 22 valuation models in 7 families (DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings).
Is Koninklijke Philips NV stock overvalued or undervalued in 2026?
As of Nov 6, 2026, PHIA trades above its calculated fair value: price €27.33, fair value €15.23, a gap of about −44% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PHIA?
No. The price is what the market pays today (€27.33); the fair value is what the company's own numbers justify (€15.23). For Koninklijke Philips NV the two are €12.10 per share apart. That gap is exactly why we show both numbers side by side.
How much is Koninklijke Philips NV worth?
The market values Koninklijke Philips NV at about €26.5B (market capitalisation, as of Nov 6, 2026). Per share that is €27.33; our models calculate a fair value of €15.23 per share.
What do the bullish and bearish scenarios say about PHIA?
Our models span a range for Koninklijke Philips NV: cautious scenario €9.63, base €15.23, optimistic €23.60 per share (as of Nov 6, 2026, price €27.33). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of PHIA?
Koninklijke Philips NV trades at a price-to-earnings ratio of 66.7 (as of Nov 6, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of €15.23 is built from several models across several years. Excluding one-off items of fiscal year 2025 it is 24.6 (reported for FY2025: 29.4). Other multiples: PEG 0.9, P/B 2.7, P/S 1.7, EV/EBITDA 14.9.
What is the PEG ratio of PHIA?
The PEG ratio of Koninklijke Philips NV is 0.95 (P/E divided by earnings growth, as of Nov 6, 2026). That is below 1, so growth is priced more cheaply than the earnings multiple alone suggests.
How solid is the balance sheet of Koninklijke Philips NV (PHIA)?
Balance-sheet figures for Koninklijke Philips NV (as of Nov 6, 2026): return on equity 8.6%, debt of 0.55 per unit of equity. They feed the Quality Score of 64/100, which measures business quality independently of the share price.
How far is PHIA from its 52-week high?
Koninklijke Philips NV trades at €27.33, about 1% below its 52-week high of €27.51 and 29% above the low of €21.11 (as of Nov 6, 2026). Distance from the high says nothing about value: that is what the fair value of €15.23 is for.
Which stocks are comparable to Koninklijke Philips NV?
From the same area (Healthcare) we also value Abbott Laboratories,, Medtronic plc, Stryker Corporation, Boston Scientific Corporation, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Koninklijke Philips NV stock attractive at the current price?
The data as of Nov 6, 2026: price €27.33, calculated fair value €15.23 (−44%), Quality Score 64/100, from 22 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PHIA calculated?
We run Koninklijke Philips NV through 22 models from 7 families: DCF Models, Earnings-Based, Dividend Discount, Multiples, Growth DCF, Economic Profit, Growth Earnings. Every model gets the same audited fundamentals; the fair value of €15.23 builds on their evidence-weighted average, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 13.3% above its aggregate fair value. Koninklijke Philips NV itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Koninklijke Philips NV (PHIA)?
The closing price on Nov 6, 2026 was €27.33. Our model-based fair value is €15.23, about 44% lower (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Koninklijke Philips NV right now?
The price sits above even our optimistic bull case (€23.60). The favourable scenario is already priced in. Solid but not exceptional quality (64/100) and above fair value, neither a clear bargain nor a standout compounder. A fairly wide model range (€9.63 to €23.60) leaves room in how you read the outcome.
Key figures of Koninklijke Philips NV
How large is the market capitalisation of Koninklijke Philips NV (PHIA)?
The market capitalisation of Koninklijke Philips NV is €26.5B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Koninklijke Philips NV (PHIA)?
The price-to-sales ratio of Koninklijke Philips NV is 3.35 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Koninklijke Philips NV (PHIA)?
Earnings per share at Koninklijke Philips NV are €0.4100 (price ÷ EPS = P/E 66.7). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Koninklijke Philips NV (PHIA)?
The dividend yield of Koninklijke Philips NV is 3.1% (payout 174%, on adjusted earnings, reported 207%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Koninklijke Philips NV (PHIA)?
The net margin of Koninklijke Philips NV is 5.0% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Koninklijke Philips NV (PHIA)?
The return on equity (ROE) of Koninklijke Philips NV is 8.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Koninklijke Philips NV (PHIA)?
On an EBIT basis the return on assets of Koninklijke Philips NV is 0.9% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Koninklijke Philips NV (PHIA)?
The operating margin of Koninklijke Philips NV is 3.8% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Koninklijke Philips NV (PHIA)?
Revenue at Koninklijke Philips NV is growing +2.1% versus a year earlier (3y avg +0.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Koninklijke Philips NV (PHIA)?
Earnings per share at Koninklijke Philips NV are growing −85.4% versus a year earlier. How much earnings per share grew versus a year earlier.
How much net debt does Koninklijke Philips NV (PHIA) carry?
The net debt of Koninklijke Philips NV is €5.3B (fiscal year 2025, ≈ 5.9 yrs of FCF). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Koninklijke Philips NV in the live analysis
One click puts Koninklijke Philips NV on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.
Some data
Nov 6, 2026